Prognosis
Treatment of HCL with purine analogs (cladribine or pentostatin) has demonstrated high rates of complete response (>75%) and prolongation of disease-free survival.[54] However, relapse is reported in approximately 50% of patients in long-term studies.[54] Median relapse-free survival of a decade or more has been reported.[6]
Use of this content is subject to our disclaimer